TokenPost·
Maze Therapeutics Posts $0.79 Q3 GAAP Loss Per Share as R&D Costs Rise
Net loss reached $48 million. Cash, cash equivalents and marketable securities totaled $477 million on Sept. 30, 2026.
More news
- TokenPostAnthropic Withdraws IPO Draft With Potential $69.3 Billion Offering
- crypto.newsFTX’s former Anthropic stake could now be worth over $30 billion
- TokenPostBrazilian Workers Claim Up to $1,000 a Month From AI Task Videos
- Crypto BriefingClaroc finds 35,578 Grok Build apps open to anyone with a link
- TokenPostCrypto Market Capitalization Fell 9.1% as AI Capex Hit $230 Billion
- TokenPostZachXBT Questions FinCEN’s Roughly $16 Billion MEXC Estimate